Our finding of selective overexpression of sTn, a reported ligand of Siglec-6, in CLL patient BMSCs is intriguing and has translational implications as it provides opportunities to target and block interactions between Siglec-6 and sTn on CLL-BMSCs, thereby inhibiting homing and/or retention of Siglec-6 + B-CLL cells to the bone marrow TME. This evidence concerns the gene EEF1A2 and B-cell chronic lymphocytic leukemia.